{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:26:12Z","timestamp":1787009172132,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Advanced glycation end products\/receptor for AGEs (AGE\/RAGE) signaling has a well-established role in the etiology of diabetic-related cardiovascular disorders. The purpose of the study was to elucidate the role of chrysin, a peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) agonist, against ischemia\/reperfusion (IR) injury in diabetic rats and its functional interaction with the AGE\/RAGE signaling pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single intraperitoneal injection of streptozotocin (STZ, 70 mg\/kg) was administered to rats for induction of diabetes. Rats having blood glucose levels more than 300 mg\/dl following a 72 hr STZ injection were classified as diabetic. PPAR-\u03b3 antagonist GW9662 (1 mg\/kg, i.p.), chrysin (60 mg\/kg, p.o.), or both were administered to diabetic rats for 4 weeks. On the 29th day, rats were given ischemia for 45 min and then reperfusion for 1 hr to induce myocardial infarction (MI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Pretreatment with chrysin significantly improved hemodynamic status, ventricular functions, and cardiac injury markers in diabetic myocardium. Increased PPAR-\u03b3\/Nrf2 and decreased RAGE protein expressions were linked to this improvement. Chrysin pretreatment resulted in the upregulation of endogenous antioxidants and reduced TBARS levels. Moreover, chrysin significantly decreased inflammation and apoptosis in diabetic myocardium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PPAR-\u03b3\/Nrf2 co-activation by chrysin ameliorated IR-induced MI in diabetic rats, possibly via modulating AGE\/RAGE signaling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgae140","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T23:24:13Z","timestamp":1729034653000},"page":"794-804","source":"Crossref","is-referenced-by-count":8,"title":["Modulation of PPAR-\u03b3\/Nrf2 and AGE\/RAGE signaling contributes to the chrysin cardioprotection against myocardial damage following ischemia\/reperfusion in diabetic rats"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9767-7525","authenticated-orcid":false,"given":"Neha","family":"Rani","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Kalpana Chawla Government Medical College , Karnal, Haryana, 132001 ,","place":["India"]},{"name":"Department of Pharmacology, All India Institute of Medical Sciences , New Delhi, 110029 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9249-9237","authenticated-orcid":false,"given":"Dharamvir Singh","family":"Arya","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences , New Delhi, 110029 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"2025060923365130200_CIT0001","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1124\/pharmrev.121.000348","article-title":"Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia\/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning","volume":"75","author":"Ferdinandy","year":"2023","journal-title":"Pharmacol Rev"},{"key":"2025060923365130200_CIT0002","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.3389\/fphys.2019.01564","article-title":"A comorbidity model of myocardial ischemia\/reperfusion injury and hypercholesterolemia in rat cardiac myocyte cultures","volume":"10","author":"Makkos","year":"2020","journal-title":"Front Physiol"},{"key":"2025060923365130200_CIT0003","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/pr.107.06002","article-title":"Interaction of cardiovascular risk factors with myocardial ischemia\/reperfusion injury, preconditioning, and postconditioning","volume":"59","author":"Ferdinandy","year":"2007","journal-title":"Pharmacol Rev"},{"key":"2025060923365130200_CIT0004","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11897-012-0089-5","article-title":"Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure","volume":"9","author":"Ramasamy","year":"2012","journal-title":"Curr Heart Fail Rep"},{"key":"2025060923365130200_CIT0005","doi-asserted-by":"publisher","first-page":"9570616","DOI":"10.1155\/2019\/9570616","article-title":"Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes","volume":"2019","author":"Yang","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"2025060923365130200_CIT0006","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10719-016-9679-x","article-title":"Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions","volume":"33","author":"Neviere","year":"2016","journal-title":"Glycoconj J"},{"key":"2025060923365130200_CIT0007","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10020-024-00905-9","article-title":"Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications","volume":"30","author":"Chen","year":"2024","journal-title":"Mol Med"},{"key":"2025060923365130200_CIT0008","doi-asserted-by":"publisher","first-page":"403460","DOI":"10.1155\/2013\/403460","article-title":"Receptor for advanced glycation end products and its involvement in inflammatory diseases","volume":"2013","author":"Chuah","year":"2013","journal-title":"Int J Inflam"},{"key":"2025060923365130200_CIT0009","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3390\/ijms17091567","article-title":"Advanced glycation end-products induce apoptosis of vascular smooth muscle cells: a mechanism for vascular calcification","volume":"17","author":"Koike","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2025060923365130200_CIT0010","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.phrs.2009.01.006","article-title":"Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease","volume":"60","author":"Yamagishi","year":"2009","journal-title":"Pharmacol Res"},{"key":"2025060923365130200_CIT0011","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.12659\/msm.907401","article-title":"Pioglitazone attenuates atherosclerosis in diabetic mice by inhibition of receptor for advanced glycation end-product (RAGE) signaling","volume":"23","author":"Gao","year":"2017","journal-title":"Med Sci Monit"},{"key":"2025060923365130200_CIT0012","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.33549\/physiolres.933439","article-title":"The role of PPARgamma in cardiovascular diseases","volume":"65","author":"Kvandov\u00e1","year":"2016","journal-title":"Physiol Res"},{"key":"2025060923365130200_CIT0013","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1677\/joe.0.1690453","article-title":"Peroxisome proliferator-activated receptors in inflammation control","volume":"169","author":"Delerive","year":"2001","journal-title":"J Endocrinol"},{"key":"2025060923365130200_CIT0014","doi-asserted-by":"publisher","first-page":"641087","DOI":"10.1155\/2012\/641087","article-title":"PPAR\u03b3 and oxidative stress: con(\u03b2) catenating NRF2 and FOXO","volume":"2012","author":"Polvani","year":"2012","journal-title":"PPAR Res"},{"key":"2025060923365130200_CIT0015","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.yjmcc.2008.10.007","article-title":"Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes","volume":"46","author":"He","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"2025060923365130200_CIT0016","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1039\/c3fo60575b","article-title":"A novel PPARgamma agonist monascin\u2019s potential application in diabetes prevention","volume":"5","author":"Hsu","year":"2014","journal-title":"Food Funct"},{"key":"2025060923365130200_CIT0017","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.freeradbiomed.2012.09.025","article-title":"Ankaflavin: a natural novel PPAR\u03b3 agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo","volume":"53","author":"Lee","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"2025060923365130200_CIT0018","doi-asserted-by":"publisher","first-page":"1378175","DOI":"10.1155\/2017\/1378175","article-title":"Collaborative power of Nrf2 and PPAR\u03b3 activators against metabolic and drug-induced oxidative injury","volume":"2017","author":"Lee","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2025060923365130200_CIT0019","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1021\/bi0159581","article-title":"Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662","volume":"41","author":"Leesnitzer","year":"2002","journal-title":"Biochemistry"},{"key":"2025060923365130200_CIT0020","doi-asserted-by":"publisher","first-page":"155233","DOI":"10.1016\/j.metabol.2022.155233","article-title":"GW9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease","volume":"133","author":"Baumann","year":"2022","journal-title":"Metabolism"},{"key":"2025060923365130200_CIT0021","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/mol.119.117887","article-title":"The peroxisome proliferator-activated receptor (PPAR)-\u03b3 antagonist 2-chloro-5-nitro-N-Phenylbenzamide (GW9662) triggers perilipin 2 expression via PPAR\u03b4 and induces lipogenesis and triglyceride accumulation in human THP-1 macrophages","volume":"97","author":"Schubert","year":"2020","journal-title":"Mol Pharmacol"},{"key":"2025060923365130200_CIT0022","doi-asserted-by":"publisher","first-page":"116797","DOI":"10.1016\/j.lfs.2019.116797","article-title":"Chrysin: pharmacological and therapeutic properties","volume":"235","author":"Naz","year":"2019","journal-title":"Life Sci"},{"key":"2025060923365130200_CIT0023","doi-asserted-by":"publisher","first-page":"17144","DOI":"10.1002\/jcp.28488","article-title":"Impact of chrysin on the molecular mechanisms underlying diabetic complications","volume":"234","author":"Farkhondeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025060923365130200_CIT0024","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00204-012-0913-4","article-title":"Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes","volume":"87","author":"Huang","year":"2013","journal-title":"Arch Toxicol"},{"key":"2025060923365130200_CIT0025","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/nu10081046","article-title":"Chrysin ameliorates malfunction of retinoid visual cycle through blocking activation of AGE-RAGE-ER stress in glucose-stimulated retinal pigment epithelial cells and diabetic eyes","volume":"10","author":"Kang","year":"2018","journal-title":"Nutrients"},{"key":"2025060923365130200_CIT0026","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/nu10070882","article-title":"Chrysin inhibits advanced glycation end products-induced kidney fibrosis in renal mesangial cells and diabetic kidneys","volume":"10","author":"Lee","year":"2018","journal-title":"Nutrients"},{"key":"2025060923365130200_CIT0027","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cbi.2016.03.015","article-title":"Chrysin, a PPAR-\u03b3 agonist improves myocardial injury in diabetic rats through inhibiting AGE-RAGE mediated oxidative stress and inflammation","volume":"250","author":"Rani","year":"2016","journal-title":"Chem Biol Interact"},{"key":"2025060923365130200_CIT0028","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12986-015-0004-7","article-title":"Inhibition of TGF-\u03b2 by a novel PPAR-\u03b3 agonist, chrysin, salvages \u03b2-receptor stimulated myocardial injury in rats through MAPKs-dependent mechanism","volume":"12","author":"Rani","year":"2015","journal-title":"Nutr Metab (Lond)"},{"key":"2025060923365130200_CIT0029","doi-asserted-by":"publisher","first-page":"173389","DOI":"10.1016\/j.ejphar.2020.173389","article-title":"Chrysin rescues rat myocardium from ischemia-reperfusion injury via PPAR-\u03b3\/Nrf2 activation","volume":"883","author":"Rani","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025060923365130200_CIT0030","doi-asserted-by":"publisher","first-page":"e82577","DOI":"10.1371\/journal.pone.0082577","article-title":"Regulation of heat shock proteins 27 and 70, p-Akt\/p-eNOS and MAPKs by Naringin Dampens myocardial injury and dysfunction in vivo after ischemia\/reperfusion","volume":"8","author":"Rani","year":"2013","journal-title":"PLoS One"},{"key":"2025060923365130200_CIT0031","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1463-1326.2011.01377.x","article-title":"Telmisartan, a dual ARB\/partial PPAR-\u03b3 agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes","volume":"13","author":"Goyal","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2025060923365130200_CIT0032","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal Biochem"},{"key":"2025060923365130200_CIT0033","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0304-4165(79)90289-7","article-title":"Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver","volume":"582","author":"Moron","year":"1979","journal-title":"Biochim Biophys Acta"},{"key":"2025060923365130200_CIT0034","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/B978-0-12-091302-2.50032-3","article-title":"Catalase","volume-title":"Methods of Enzymatic Analysis","author":"Aebi","year":"1974"},{"key":"2025060923365130200_CIT0035","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.diabres.2013.01.008","article-title":"Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy","volume":"100","author":"Lee","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2025060923365130200_CIT0036","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4093\/dmj.2014.38.5.337","article-title":"Diabetic cardiomyopathy and its prevention by nrf2: current status","volume":"38","author":"Chen","year":"2014","journal-title":"Diabetes Metab J"},{"key":"2025060923365130200_CIT0037","doi-asserted-by":"publisher","first-page":"6437467","DOI":"10.1155\/2017\/6437467","article-title":"Insights for oxidative stress and mTOR Signaling in myocardial ischemia\/reperfusion injury under diabetes","volume":"2017","author":"Zhao","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"2025060923365130200_CIT0038","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2014.01.065","article-title":"Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis","volume":"728","author":"Mantawy","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2025060923365130200_CIT0039","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbi.2019.01.001","article-title":"Down-regulation of myocardial infarction associated transcript 1 improves myocardial ischemia-reperfusion injury in aged diabetic rats by inhibition of activation of NF-\u03baB signaling pathway","volume":"300","author":"Liu","year":"2019","journal-title":"Chem Biol Interact"},{"key":"2025060923365130200_CIT0040","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2014.05.007","article-title":"Chrysin, an anti-inflammatory molecule, abrogates renal dysfunction in type 2 diabetic rats","volume":"279","author":"Ahad","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025060923365130200_CIT0041","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.bcp.2014.03.016","article-title":"Chrysin attenuates inflammation by regulating M1\/M2 status via activating PPAR\u03b3","volume":"89","author":"Feng","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"2025060923365130200_CIT0042","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.14670\/HH-11-641","article-title":"Chrysin attenuates cardiomyocyte apoptosis and loss of intermediate filaments in a mouse model of mitoxantrone cardiotoxicity","volume":"30","author":"Anghel","year":"2015","journal-title":"Histol Histopathol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/6\/794\/60924768\/rgae140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/77\/6\/794\/60924768\/rgae140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T23:37:00Z","timestamp":1749512220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/77\/6\/794\/7914040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11,29]]},"published-print":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgae140","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,11,29]]}}}